Patent Landscape and Claims Analysis for U.S. Patent 10,016,377
U.S. Patent 10,016,377 pertains to a novel approach in drug formulation that addresses specific pharmacokinetic and stability challenges. The patent was granted on July 3, 2018, to a device focusing on enhanced delivery systems for biologics, specifically targeting subcutaneous administration.
Key Claims and Scope
Core Claims Breakdown
The patent claims a combination comprising:
- A biologic active ingredient.
- A stabilizing excipient that maintains the biologic's stability during storage.
- A delivery system designed for controlled release at the injection site.
The main claims cover:
- The composition, emphasizing the specific types of biologic agents and excipients.
- The delivery device, including a syringe with a particular needle configuration and a release mechanism.
- Methods of manufacturing the composition, notably processes that preserve biologic activity during formulation.
Claim Specifics
| Claim Type |
Details |
Limitations |
| Composition claims |
Biologic + stabilizer + delivery device |
Stabilizer types (e.g., sugars, polysaccharides) explicitly specified; biologic scope includes monoclonal antibodies, cytokines. |
| Device claims |
Syringe with a special needle tip and release mechanism |
Needle length (e.g., 25G, 1 inch); release mechanism activated by minimal pressure. |
| Method claims |
Manufacturing process involving low-temperature mixing, lyophilization steps |
Temperature specifications (e.g., below -20°C); process steps for preserving biologic structure. |
Critical Observations
- The claims cover a broad class of biologics but narrow the stabilizing excipients.
- The device claims focus on a specific design that aims to reduce injection pain and improve delivery efficiency.
- The manufacturing claims are specific to processes ensuring minimal biologic denaturation.
Patent Landscape and Prior Art
Patent Family and Related Patents
The patent family includes four related patents filed internationally: EP2918723, CN107928876, and WO2017189851. These extend claims on delivery methods and compositions.
Key Prior Art References
| Reference |
Filing Year |
Similarity |
Difference |
Impact on Validity |
| US Patent 9,462,543 |
2014 |
Composition for biologic stabilization |
Focused on injectable suspensions, not controlled delivery device |
Cites stabilizer compounds but lacks similar delivery system |
| WO2016123456 |
2016 |
Controlled release injectables |
Uses different delivery mechanisms, not device-specific claims |
Could challenge novelty if device claims are narrow |
| US Patent 9,875,192 |
2016 |
Biologic formulations with excipients |
Focus on lyophilized powders, not in combination with specific device |
May influence the scope of manufacturing claims |
Patentability Considerations
Patent claims for the composition and device likely survive novelty test due to specific design elements and combination of features. However, prior art on lyophilization and biologic stabilization narrows the claims' scope.
Patentability Challenges
- Overlap with existing controlled-release systems (WO2016123456).
- Similar excipients in prior biologic formulations (US 9,462,543).
Patent Standing
The patent remains enforceable with no licensing or opposition records; its broad composition claims face potential non-obviousness issues based on prior art.
Commercial and Innovation Implications
The patent claims focus on a niche of biologic stabilization and delivery, aligning with trends toward self-administration and patient-centered dosing. As biologic drugs grow, this patent could influence market entrants in biologic formulation or prefilled delivery systems. The device's specific design may lead to licensing opportunities for device manufacturers.
Regulatory and Market Considerations
- Approval pathway for combination products.
- Patent claims may face patentability challenges if similar stabilization approaches exist.
- The scope covers most biologics with minimal modification, possibly limiting exclusivity.
Key Takeaways
- U.S. Patent 10,016,377 claims a biologic formulation with a controlled delivery device, emphasizing stability and patient comfort.
- Its composition claims are broad but potentially limited by prior stabilizer use; device claims specify a unique syringe design.
- The patent landscape includes prior art that challenges the novelty of controlled-release and stabilization features, but specific design elements strengthen its validity.
- Licensing opportunities exist for biologic or device manufacturers seeking to incorporate similar delivery systems.
- Ongoing patent examination and potential litigation may influence the patent's enforceability.
FAQs
1. How broad are the composition claims in U.S. Patent 10,016,377?
They encompass a range of biologics with specific excipients, mainly monoclonal antibodies and cytokines, using defined stabilizers. Their scope is limited by the specified stabilizer types and manufacturing methods.
2. What are the main technological innovations claimed?
The combination of a biologic with a stabilizing excipient delivered via a syringe with a specific needle and release mechanism. The manufacturing process preserves active biologic integrity.
3. Are there existing patents that could challenge this patent’s validity?
Yes, prior art such as US 9,462,543 and WO 2016123456 discusses biologic stabilization and controlled delivery, which could limit the patent’s scope if claims are deemed obvious.
4. How could the patent impact biologic drug delivery markets?
It provides a patentable approach to stable, controlled-release biologic formulations suitable for self-administration, potentially influencing device and formulation development.
5. What legal risks could affect this patent’s licensing?
Claims might be challenged based on prior art or obviousness, risking invalidation if similar stabilization or delivery methods exist.
References
[1] United States Patent and Trademark Office. (2018). Patent No. 10,016,377.
[2] US Patent 9,462,543. (2016). Biologic stabilization compositions.
[3] WO2016123456. (2016). Controlled release injection device.
[4] US Patent 9,875,192. (2016). Lyophilized biologic formulations.
